Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 3 2Phase 4 1

Status

Suspended 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1CNS 1

Conditions

Meningioma 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 273Magnetic Resonance Spectroscopy 224pembrolizumab 214Carboplatin 173Biopsy 166Cisplatin 159Nivolumab 149Cyclophosphamide 133Radiotherapy 117Paclitaxel 117Gemcitabine 112Bevacizumab 92durvalumab 86Dexamethasone 80Rituximab 76Oxaliplatin 73atezolizumab 68Capecitabine 67venetoclax 66Fluorouracil 66Doxorubicin 65Docetaxel 65Etoposide 63Radiosurgery 60Radiation 57Prednisone 57Cytarabine 56Ipilimumab 55Pemetrexed 54Taxes 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Hydroxyurea × 90 days × Clear all
NCT05020652 2026-06-02

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
107 enrolled
Lymphoid

Lymphoma, Follicular

NCT06955169 2026-05-22

MOMENTUM-1

RTOG Foundation, Inc.

Phase 2 Suspended
153 enrolled
CNS

Meningioma

NCT06930352 2026-03-13

Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

Ohio State University Comprehensive Cancer Center

Phase 2 Not yet recruiting
70 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡